Marker Therapeutics (MRKR) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Marker Therapeutics has announced significant strides in its immuno-oncology programs, including promising preliminary results from its lymphoma treatment study and strategic funding gains. The biotech firm secured a $2 million grant from the NIH to support its Acute Myeloid Leukemia treatment program and received an Orphan Drug Designation in Europe, while also making key leadership appointments and extending its financial runway into late 2025.
For further insights into MRKR stock, check out TipRanks’ Stock Analysis page.
